The Future of Pharmaceutical Innovation
Leveraging cutting-edge technology and AI-driven solutions to revolutionize drug discovery, development, and delivery for better patient outcomes.
About Us
At PDA Pharma, we bridge science and wellness by providing cutting-edge compounded formulations, especially tailored injectables that improve quality of life, metabolism, and cellular health. We serve licensed healthcare professionals and clinics with precision, compliance, and care.
NAD+ Pen
Experience the future of wellness with PDA Pharma’s NAD+ Pen — a revolutionary delivery system designed for rapid absorption and convenience. NAD+ supports cellular energy, improves mental clarity, promotes healthy aging, and boosts overall vitality. Trusted by health professionals, our NAD+ Pen helps you restore and maintain peak performance. Feel energized. Stay sharp. Live better.
Tirzepatide (GLP-1/GIP Agonist)
Tirzepatide is used for type 2 diabetes to help improve blood sugar levels. In type 2 diabetes, tirzepatide decreases blood sugar levels by helping release insulin when blood sugar levels are high, lowering the amount of sugar the liver makes, and slowing food movement through the intestines. Tirzepatide should be used together with diet and exercise.
Tirzepatide is FDA-approved to treat adults with type 2 diabetes and should be used together with diet and exercise. It can be used as a single therapy (on its own) or with other diabetes medicines, including sulfonylureas, SGLT2 inhibitors, or metformin.
It is not known if tirzepatide can be used in people who have had pancreatitis. Tirzepatide should not be used in people who have type 1 diabetes.
Our product is licensed under DMF 39900 type A
Retatrutide 40mg
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively.
The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF.
Here, in this randomized, double-blind, placebo-controlled trial, participants (n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 10mg dose) or placebo.
PDA Gold somatropin
PDA Gold (Somatropin) is an advanced recombinant human growth hormone formulation designed to support metabolic, aesthetic, and functional benefits. A 48-week clinical study demonstrated significant improvements in body composition, including increased lean body mass and reductions in total body fat.
The primary objective of recent research was to assess mean relative change from baseline in lean muscle mass at 24 weeks in participants with metabolic dysfunction and excess body fat.
In this randomized, double-blind, placebo-controlled trial, participants (n = 120) were randomly assigned to 48 weeks of daily subcutaneous PDA Gold (somatropin, 1, 2, 4, or 6 mg dose) or placebo.
